XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Business Combination - Consideration (Details)
$ in Thousands
12 Months Ended
Jan. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Business Combination    
Additional contingent consideration recognized   $ 701
Contingent consideration payment   2,500
Epiluvac AB    
Business Combination    
Business Combination, Contingent Consideration, Liability, Measurement Input us-gaap:MeasurementInputDiscountRateMember  
Epiluvac AB    
Business Combination    
Cash paid, net of cash acquired $ 30,373  
Contingent consideration 26,055  
Acquisition date fair value $ 56,428  
Contingent consideration measurement input 0.0554  
Contingent consideration $ 26,100 24,200
Additional contingent consideration recognized   700
Contingent consideration payment   2,500
Epiluvac AB | Accrued expenses and other current liabilities    
Business Combination    
Contingent consideration   1,800
Epiluvac AB | Other liabilities.    
Business Combination    
Contingent consideration   $ 22,400
Epiluvac AB | Completion of certain defined milestones    
Business Combination    
Contingent consideration payments, High end of range 15,000  
Epiluvac AB | Percentage of orders received during defined Earn-out period    
Business Combination    
Contingent consideration payments, High end of range $ 20,000  
Maximum earn-out period 4 years